Morria Biopharmaceuticals Announces Promising Asthma Pre-Clinical Results for Treatment of Asthma
Posted on: Wednesday, 27 July 2005, 12:00 CDT
Morria Biopharmaceuticals Plc., a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that its leading inhaled drug candidate (termed MRX3) markedly ameliorated asthma symptoms and reduced the levels of several key inflammatory mediators in pre-clinical trials in animals. The results of these studies, conducted by Professor Saul Yedgar of the Hebrew University and his collaborators, appear in the current issue of Thorax.
In the study, rats with ovalbumin-induced asthma were pre-treated with inhaled MRX3 to test for the drug's efficacy as an asthma preventative therapy. MRX3 was compared to a placebo as well as a standard steroid (dexamethosone). The results show that MRX3 inhalation markedly ameliorated airway-constriction and airway inflammation and suppressed levels of the key inflammatory mediator associated with asthma: cysteinyl-leukotrienes, TNF-alpha and nitric oxide in lung macrophages. Furthermore, the drug had promising efficacy even when given after the asthma attack had already commenced, indicating a possible "reliever" function as well as a "preventer" function.
"This looks like a promising new approach" said Professor Peter J. Barnes of Imperial College in London, an advisor to Morria its asthma development program.
"This is yet another promising indication of the considerable potential of our drug technology in treating chronic inflammatory diseases and replacing current therapies, particularly corticosteroids" said Dr. Yuval Cohen, Managing Director of Morria Biopharmaceuticals. "Our strategic goal is to initiate clinical trials in patients as soon as possible while continuing our synergistic efforts with our other leading products in the fields of dermatology and gastro-intestinal inflammation."
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc. is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, lung and gastro-intestinal inflammatory diseases.
This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information
Source: Business Wire
Related Articles
- Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
- No-Drug, Anti-Inflammatory Diet Yields Positive Clinical-Trial Results, Including Marked Improvement of Metabolic Abnormalities and Rapid Weight Loss
- Firm Promises More Anti-Bird Flu Drug
- FDA Panel: Asthma Drugs Should Stay on Market
- Panel says 3 asthma drugs should stay on market
- FDA Considers Withdrawal of Asthma Drugs
- Safety of Three Asthma Drugs is Considered
- US asks if 3 asthma drugs should stay on market
- U.S. asks if 3 asthma drugs should stay on market
- Hopes of Cure for Miscarriage; Scientist Uncovers Positive Side-Effect of Asthma Drug
 |
 |
User Comments (0)
RSS Feeds